Literature DB >> 22288002

Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage.

Subrata Haldar1, Aruna Basu.   

Abstract

The disorder of microRNAs (miRNAs) often referred as 'micromanagers of gene expression' has been implicated with a vast array of neoplasmthe discovery establishes an important connection with the etiology, diagnosis and potential therapy of human cancer. Indeed, the wide range of profiling studies enabled to create miRNA signatures of solid tumors as well as cancers of blood origin. MiRNAs have been observed to play a significant role in the regulation of gene expression-a critical aspect of many biological processes, including cell development, differentiation, apoptosis and proliferation. The differential expression levels of miRNAs in tumors and their normal counterpart have enabled scientists to designate their roles as oncomir or tumor suppressor. Interestingly, the diminishment of oncogenic or enhanced levels of tumor suppressor miRNAs (antagomirs) have been reported to modulate the sensitivity of cancer cells to anticancer agents. To the other end, carcinogenic chemicals either possess the ability of silencing beneficial tumor suppressive miRNAs or maintain the augmented levels of their oncogenic counterpart. In this article we provide a comprehensive overview on the modulation of these "micromanaging oligos" by cancer causing as well as cancer preventing agents.

Entities:  

Year:  2011        PMID: 22288002      PMCID: PMC3266367     

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  57 in total

Review 1.  Growth factor signaling and resistance to cancer chemotherapy.

Authors:  Zunyan Dai; Ying Huang; Wolfgang Sadée
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 2.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

3.  Prediction of anticancer drug potency from expression of genes involved in growth factor signaling.

Authors:  Zunyan Dai; Catalin Barbacioru; Ying Huang; Wolfgang Sadée
Journal:  Pharm Res       Date:  2006-01-26       Impact factor: 4.200

4.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Authors:  Mark Bloomston; Wendy L Frankel; Fabio Petrocca; Stefano Volinia; Hansjuerg Alder; John P Hagan; Chang-Gong Liu; Darshna Bhatt; Cristian Taccioli; Carlo M Croce
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

5.  MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma.

Authors:  Michele Avissar; Brock C Christensen; Karl T Kelsey; Carmen J Marsit
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

7.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

8.  Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells.

Authors:  Pei-Yin Hsu; Daniel E Deatherage; Benjamin A T Rodriguez; Sandya Liyanarachchi; Yu-I Weng; Tao Zuo; Joseph Liu; Alfred S L Cheng; Tim H-M Huang
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

10.  MicroRNAs modulate the chemosensitivity of tumor cells.

Authors:  Paul E Blower; Ji-Hyun Chung; Joseph S Verducci; Shili Lin; Jong-Kook Park; Zunyan Dai; Chang-Gong Liu; Thomas D Schmittgen; William C Reinhold; Carlo M Croce; John N Weinstein; Wolfgang Sadee
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

View more
  4 in total

1.  miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.

Authors:  A A Takwi; Y-M Wang; J Wu; M Michaelis; J Cinatl; T Chen
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Surprisal analysis of Glioblastoma Multiform (GBM) microRNA dynamics unveils tumor specific phenotype.

Authors:  Sohila Zadran; Francoise Remacle; Raphael Levine
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

3.  Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R.

Authors:  Lulu Farhana; Marcia I Dawson; Farhan Murshed; Jayanta K Das; Arun K Rishi; Joseph A Fontana
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

Review 4.  Advances in the Antagonism of Epigallocatechin-3-gallate in the Treatment of Digestive Tract Tumors.

Authors:  Changwei Liu; Penghui Li; Zhihao Qu; Wei Xiong; Ailing Liu; Sheng Zhang
Journal:  Molecules       Date:  2019-05-03       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.